ANIK Anika Therapeutics Inc.

Anika to Issue Second Quarter 2020 Financial Results and Business Highlights on Thursday, July 30

Anika to Issue Second Quarter 2020 Financial Results and Business Highlights on Thursday, July 30

BEDFORD, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced that the Company plans to issue its second quarter 2020 financial results after the close of the market on Thursday, July 30, 2020 and hold its investor conference call on the same day, Thursday, July 30, 2020, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.

The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and providing the conference ID number 10010333. A live audio webcast will be available in the "Investor Relations" section of Anika's website, . An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics

(NASDAQ: ANIK), is a global, integrated joint preservation, restoration and regenerative solutions company based in Bedford, Massachusetts. Anika is committed to delivering a diverse array of products to improve the lives of patients, with a focus on osteoarthritis pain management, sports medicine and joint preservation, restoration and regeneration. The Company has close to three decades of global expertise commercializing innovative products across the orthopedic early intervention continuum of care. For more information about Anika, please visit .

For Investor Inquiries:

Anika Therapeutics, Inc.

Sylvia Cheung, 781-457-9000

Chief Financial Officer



For Media Inquiries:

W2O Group

Rachel Girard, 617-379-6760

EN
16/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anika Therapeutics Inc.

 PRESS RELEASE

Anika Reports First Quarter 2025 Financial Results

Anika Reports First Quarter 2025 Financial Results First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early interventio...

 PRESS RELEASE

Anika to Participate in the Sidoti Virtual Investor Conference

Anika to Participate in the Sidoti Virtual Investor Conference BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Wednesday, May 21, 2025. Anika will host a virtual presentation with Q&A starting at 1:00pm ET. Webcast of the presentation and Q&A will be available in the  section of Anika’s website, . An archive of the presentation will also be a...

 PRESS RELEASE

Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, ...

Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025 BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID numb...

 PRESS RELEASE

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the Osteoarthritis (“OA”) Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced that on April 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $15.03, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly ...

 PRESS RELEASE

Anika Reports Fourth Quarter and Full Year 2024 Financial Results

Anika Reports Fourth Quarter and Full Year 2024 Financial Results Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Ani...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch